問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Thoracic Medicine

更新時間:2023-09-19

陳燕溫
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

9Cases

2022-09-01 - 2025-02-14

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-06-30 - 2024-10-15

Phase II/III

Completed
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
4Sites

Terminated4Sites

2023-08-31 - 2032-02-12

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2023-08-01 - 2028-02-29

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting1Sites

2024-01-01 - 2027-02-28

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2022-12-07 - 2023-06-21

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus
  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2017-06-01 - 2019-12-31

Phase II

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia
  • Condition/Disease

    Pseudomonas Aeruginosa Pneumonia

  • Test Drug

    Aerucin(aerubumab,AR-105)

Participate Sites
11Sites

Terminated10Sites

2019-05-01 - 2021-12-30

Phase III

A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
  • Condition/Disease

    Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

  • Test Drug

    Sulbactam-ETX2514 (ETX2514SUL)

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites